Tesamorelin // FDA-Approved GHRH
The only FDA-approved growth hormone secretagogue for body composition. A 44-amino acid synthetic GHRH analog with a trans-3-hexenoic acid modification that enhances potency and stability. Specifically approved for HIV-associated lipodystrophy and aggressively studied for visceral fat reduction, NAFLD, and cognitive preservation.
Visceral fat. The FDA listened.
Tesamorelin is full-length GHRH(1-44) with a trans-3-hexenoic acid group added to the N-terminus. This modification enhances receptor affinity and resists DPP-IV enzymatic degradation. Like sermorelin, it stimulates pulsatile GH release from the pituitary — but with greater potency. The FDA approved it specifically because clinical trials demonstrated significant visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy.
2mg daily. The FDA-validated dose.
Tesamorelin is dosed at 2mg subcutaneously once daily, typically in the abdomen. Unlike sermorelin, it doesn't require bedtime dosing specifically — though many practitioners still prefer evening administration to align with the nocturnal GH pulse. The FDA approval was based on the 2mg daily dose with 6–12 month treatment periods.
The GH peptide with FDA muscle behind it.
Tesamorelin was developed by Theratechnologies and approved by the FDA in 2010 for HIV-associated lipodystrophy. Phase 3 trials demonstrated a significant reduction in trunk fat (visceral adipose tissue) of approximately 15–18% at 26 weeks without significant changes in subcutaneous fat or lean mass loss.
Beyond lipodystrophy, tesamorelin has been studied for NAFLD (non-alcoholic fatty liver disease), where it showed significant reduction in hepatic fat fraction. Additionally, the HATIM trial suggested potential cognitive benefits — GH-deficient adults treated with tesamorelin showed improved executive function and verbal memory.
The compound has the strongest clinical evidence of any GH secretagogue for body composition. Its advantage over exogenous HGH is that it preserves pulsatile physiology and has a significantly better safety profile — no supraphysiological GH levels, no direct IGF-1 injection risks.
Tesamorelin vs. the GH secretagogue field.
| Compound | FDA Status | Primary Use | GH Potency | Data Quality |
|---|---|---|---|---|
| Tesamorelin | Approved | Visceral fat / NAFLD | Strong | Phase 3 RCTs |
| Sermorelin | Diagnostic | Anti-aging / GH deficiency | Moderate | Clinical + off-label |
| CJC-1295 (no DAC) | Research | GH optimization | Strong | Limited clinical |
| MK-677 | Research | Oral GH elevation | Moderate | Phase 2 |
| Exogenous HGH | Approved | GH deficiency | Supraphysiological | Extensive |
What to watch for.
Tesamorelin's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Injection site reactions (erythema, pruritus — most common)
- Arthralgia (joint pain, GH-mediated)
- Peripheral edema (water retention)
- Myalgia (muscle pain)
- Paresthesia (tingling in extremities)
- Nausea (uncommon)
- Hypersensitivity reactions (rare)
- Effect reversal after discontinuation (VAT may return)
- IGF-1 (primary efficacy marker)
- Fasting glucose and insulin (GH affects glucose metabolism)
- HbA1c (monitor every 3 months)
- Thyroid panel (GH affects T4→T3 conversion)
- Liver function panel (ALT, AST — especially for NAFLD indication)
- Cortisol (morning draw)
- Lipid panel (VAT reduction may improve lipids)
- DEXA scan or waist circumference (VAT tracking)
- Can pair with Ipamorelin for GHRH + GHRP synergy
- BPC-157 for GI and tissue support
- MOTS-C for additional metabolic optimization
- Do NOT combine with other GHRH analogs (Sermorelin, CJC-1295)
- Do NOT combine with exogenous HGH
- Monitor glucose carefully — FDA-level compound, respect the pharmacology
- Egrifta SV: room temperature storage (brand product)
- Compounded: refrigerate at 2–8°C (36–46°F)
- Reconstituted: use immediately or within 24 hours (brand)
- Compounded reconstituted: refrigerate, use within 21–28 days
- Protect from light
- Pharmaceutical grade available via prescription
Compounds that complement Tesamorelin.
The only GH secretagogue with FDA validation for body composition.
Tesamorelin is the gold standard if your priority is evidence-based body composition improvement with GH secretagogue therapy. It has Phase 3 RCT data, FDA approval, and specific visceral fat reduction efficacy that no other GH peptide can match. The trade-off: it's more expensive than CJC-1295 or sermorelin (especially brand Egrifta), and its effects reverse after discontinuation. If you want the compound with the most clinical muscle behind it — and you can afford it — tesamorelin is the answer.
Our free Protocol Guide includes the complete Tesamorelin protocol — FDA dosing, visceral fat tracking, IGF-1 optimization, and blood work panels.